JesÃºs Oria-HernÃ¡ndez

List of Publications by Year
in descending order

30 papers	527 citations	623734 14 h-index	642732 23 g-index
30 all docs	30 docs citations	30 times ranked	873 citing authors

#	Article	IF	Citations
1	The Stability of G6PD Is Affected by Mutations with Different Clinical Phenotypes. International Journal of Molecular Sciences, 2014, 15, 21179-21201.	4.1	57
2	Pyruvate Kinase Revisited. Journal of Biological Chemistry, 2005, 280, 37924-37929.	3.4	52
3	Determining the molecular mechanism of inactivation by chemical modification of triosephosphate isomerase from the human parasite Giardia lamblia: A study for antiparasitic drug design. Proteins: Structure, Function and Bioinformatics, 2011, 79, 2711-2724.	2.6	41
4	Giardial Triosephosphate Isomerase as Possible Target of the Cytotoxic Effect of Omeprazole in Giardia lamblia. Antimicrobial Agents and Chemotherapy, 2014, 58, 7072-7082.	3.2	34
5	The nuclear receptor FXR, but not LXR, up-regulates bile acid transporter expression in non-alcoholic fatty liver disease. Annals of Hepatology, 2015, 14, 487-93.	1.5	31
6	Dichotomic Phylogenetic Tree of the Pyruvate Kinase Family. Journal of Biological Chemistry, 2006, 281, 30717-30724.	3.4	29
7	Disulfiram as a novel inactivator of Giardia lamblia triosephosphate isomerase with antigiardial potential. International Journal for Parasitology: Drugs and Drug Resistance, 2017, 7, 425-432.	3.4	28
8	Synthesis of nitro(benzo)thiazole acetamides and in vitro antiprotozoal effect against amitochondriate parasites Giardia intestinalis and Trichomonas vaginalis. Bioorganic and Medicinal Chemistry, 2015, 23, 2204-2210.	3.0	27
9	Cloning, Expression, Purification and Characterization of His-Tagged Human Glucose-6-Phosphate Dehydrogenase: A Simplified Method for Protein Yield. Protein Journal, 2013, 32, 585-592.	1.6	24
10	Structural and Functional Perturbation of Giardia lamblia Triosephosphate Isomerase by Modification of a Non-Catalytic, Non-Conserved Region. PLoS ONE, 2013, 8, e69031.	2.5	20
11	Allosteric Interactions by p53 mRNA Govern HDM2 E3 Ubiquitin Ligase Specificity under Different Conditions. Molecular and Cellular Biology, 2016, 36, 2195-2205.	2.3	20
12	Novel giardicidal compounds bearing proton pump inhibitor scaffold proceeding through triosephosphate isomerase inactivation. Scientific Reports, 2017, 7, 7810.	3.3	20
13	Structural Effects of Protein Aging: Terminal Marking by Deamidation in Human Triosephosphate Isomerase. PLoS ONE, 2015, 10, e0123379.	2.5	18
14	Biochemical Analysis of Two Single Mutants that Give Rise to a Polymorphic G6PD A-Double Mutant. International Journal of Molecular Sciences, 2017, 18, 2244.	4.1	16
15	Species-Specific Inactivation of Triosephosphate Isomerase from Trypanosoma brucei: Kinetic and Molecular Dynamics Studies. Molecules, 2017, 22, 2055.	3.8	14
16	The E104D mutation increases the susceptibility of human triosephosphate isomerase to proteolysis. Asymmetric cleavage of the two monomers of the homodimeric enzyme. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2013, 1834, 2702-2711.	2.3	13
17	Kinetics of the thermal inactivation and aggregate formation of rabbit muscle pyruvate kinase in the presence of trehalose. Archives of Biochemistry and Biophysics, 2009, 490, 129-136.	3.0	11
18	The active (ADHa) and inactive (ADHi) forms of the PQQ-alcohol dehydrogenase from Gluconacetobacter diazotrophicus differ in their respective oligomeric structures and redox state of their corresponding prosthetic groups. FEMS Microbiology Letters, 2012, 328, 106-113.	1.8	11

#	Article	IF	Citations
19	Cloning, Expression and Characterization of Recombinant, NADH Oxidase from Giardia lamblia. Protein Journal, 2016, 35, 24-33.	1.6	11
20	Selectivity of pyruvate kinase for Na+ and K+ in water/dimethylsulfoxide mixtures. FEBS Journal, 2003, 270, 2377-2385.	0.2	10
21	RNAi-Mediated Specific Gene Silencing as a Tool for the Discovery of New Drug Targets in Giardia lamblia; Evaluation Using the NADH Oxidase Gene. Genes, 2017, 8, 303.	2.4	10
22	The Role of Epigenetics in the Progression of Non-Alcoholic Fatty Liver Disease. Mini-Reviews in Medicinal Chemistry, 2015, 15, 1187-1194.	2.4	10
23	The Contribution of Water to the Selectivity of Pyruvate Kinase for Na+ and K+. FEBS Journal, 1997, 250, 583-589.	0.2	7
24	Biochemical, Kinetic, and Computational Structural Characterization of Shikimate Kinase from Methicillin-Resistant Staphylococcus aureus. Molecular Biotechnology, 2019, 61, 274-285.	2.4	5
25	Design, synthesis, kinetic, molecular dynamics, and hypoglycemic effect characterization of new and potential selective benzimidazole derivatives as Protein Tyrosine Phosphatase 1B inhibitors. Bioorganic and Medicinal Chemistry, 2021, 48, 116418.	3.0	3
26	Structure-based identification of a potential non-catalytic binding site for rational drug design in the fructose 1,6-biphosphate aldolase from Giardia lamblia. Scientific Reports, 2019, 9, 11779.	3.3	2
27	Benzimidazole Derivatives as New and Selective Inhibitors of Arginase from Leishmania mexicana with Biological Activity against Promastigotes and Amastigotes. International Journal of Molecular Sciences, 2021, 22, 13613.	4.1	2
28	Proteomics: a tool to develop novel diagnostic methods and unravel molecular mechanisms of pediatric diseases. BoletÃn MÃ©dico Del Hospital Infantil De MÃ©xico, 2017, 74, 233-240.	0.3	1
29	Proteins in Waterâ€“Cosolvent Binary Systems: Function and Structure. , 0, , 6310-6324.		0
30	Kinetic stability of the water-forming NADH oxidase from Giardia lamblia: implications for biotechnological processes. Biotechnology and Biotechnological Equipment, 2021, 35, 1401-1408.	1.3	0